SEC Tracker
Get the app

Eupraxia Pharmaceuticals EPRX

Eupraxia Pharmaceuticals reports third quarter 2026 financial results

Eupraxia Pharmaceuticals (EPRX) filed a 6-K with the SEC on Nov 10, 2026, 4:01 pm ET. Source: the filing on SEC EDGAR.

Foreign issuer report

Form
6-K
Filed
Importance
Notable
  1. Net loss of $15.2 million for Q3 2026
  2. Cash and cash equivalents of $75.2 million as of September 30, 2026
  3. Cash runway into the second half of 2028
  4. Reached target enrollment of 120 patients in Phase 2b RESOLVE trial

Written from the 6-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Eupraxia Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.